Good evening :)
$
₹
ICON PLC

ICON PLC

ICLR

NASDAQ
Asset Logo

ICON PLC

ICLR

NASDAQ
$168.900.23% (-0.40)
$
₹
$168.900.23% (-0.40)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Diagnostics & Research

Large Cap

With a market cap of $13.1B the stock is ranked 820

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

264.54
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.39
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.64
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.51
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0.33%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 17 analysts' reports

Buy
11 analysts
Hold
6 analysts
Sell
0 analyst

Analysts expect a +9.85% price upside over the next year

Current Price$168.90
Target Price$185.56

Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Peers

Peers

Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
32.78
32.78
1Y Return
29.33%
29.33%
Buy Reco %
80.64
80.64
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
P/E Ratio
32.55
32.55
1Y Return
42.85%
42.85%
Buy Reco %
69.56
69.56
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
28.98
28.98
1Y Return
17.18%
17.18%
Buy Reco %
82.35
82.35
Waters Corporation
WAT
Waters Corporation
P/E Ratio
103.11
103.11
1Y Return
37.1%
37.1%
Buy Reco %
31.81
31.81
Illumina Inc
ILMN
Illumina Inc
P/E Ratio
38.44
38.44
1Y Return
106.31%
106.31%
Buy Reco %
55.00
55.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
ICON PLC 264.541.390.51
Thermo Fisher Scientific Inc32.784.281.81
IQVIA Holdings Inc32.556.980.95

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

2
0
2.1
-0.1
2
0.1
2
0
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue2.092.122.032.0422.012.042.182.032.06
Net Income0.180.140.190.250.150.180-0.110.100.07
Net Profit Margin8.96%6.92%9.71%12.73%7.70%9.06%0.11%-5.02%5.15%3.51%
See CostsAll values in $ Billion

Frequently asked questions

Frequently asked questions

  1. ICON PLC (ICLR) share price today is $168.90 as of September 15, 2026 at 1:30 AM IST. The stock touched a day high of $173.36 and a day low of $168.20.

  2. ICON PLC stock trades on NASDAQ under the ticker symbol ICLR.

  3. ICON PLC's market capitalization is $13.06B as of September 15, 2026 at 1:30 AM IST.

  4. ICON PLC's price-to-earnings (P/E) ratio is 264.54 as of September 15, 2026.

  5. ICON PLC's price-to-book (P/B) ratio is 1.39 as of September 15, 2026.

  6. Yes, You can buy ICON PLC shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy ICON PLC shares in three steps: 1. Search ICON PLC on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since ICON PLC trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in ICON PLC (ICLR) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0592 shares at the current price of $168.90.

Loading...